JP2009525283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009525283A5 JP2009525283A5 JP2008552504A JP2008552504A JP2009525283A5 JP 2009525283 A5 JP2009525283 A5 JP 2009525283A5 JP 2008552504 A JP2008552504 A JP 2008552504A JP 2008552504 A JP2008552504 A JP 2008552504A JP 2009525283 A5 JP2009525283 A5 JP 2009525283A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- collagenase
- mixture
- measured
- high performance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 79
- 108060005980 Collagenase Proteins 0.000 claims description 24
- 102000029816 Collagenase Human genes 0.000 claims description 24
- 229960002424 collagenase Drugs 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 231100000241 scar Toxicity 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 208000035484 Cellulite Diseases 0.000 claims description 4
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 208000002260 Keloid Diseases 0.000 claims description 4
- 206010024612 Lipoma Diseases 0.000 claims description 4
- 206010049752 Peau d'orange Diseases 0.000 claims description 4
- 206010034464 Periarthritis Diseases 0.000 claims description 4
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000036232 cellulite Effects 0.000 claims description 4
- 230000000994 depressogenic effect Effects 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 210000001117 keloid Anatomy 0.000 claims description 4
- 230000001613 neoplastic effect Effects 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 230000002390 hyperplastic effect Effects 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 62
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims 21
- 238000001914 filtration Methods 0.000 claims 14
- 238000004007 reversed phase HPLC Methods 0.000 claims 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 10
- 229930006000 Sucrose Natural products 0.000 claims 10
- 239000007983 Tris buffer Substances 0.000 claims 10
- 239000005720 sucrose Substances 0.000 claims 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 10
- 239000007972 injectable composition Substances 0.000 claims 9
- 238000003756 stirring Methods 0.000 claims 8
- 238000003556 assay Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 238000011084 recovery Methods 0.000 claims 6
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 claims 5
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 claims 5
- 108010052968 leupeptin Proteins 0.000 claims 5
- 239000001888 Peptone Substances 0.000 claims 4
- 108010080698 Peptones Proteins 0.000 claims 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims 4
- 238000000855 fermentation Methods 0.000 claims 4
- 230000004151 fermentation Effects 0.000 claims 4
- 239000000706 filtrate Substances 0.000 claims 4
- 235000019319 peptone Nutrition 0.000 claims 4
- 208000004362 Penile Induration Diseases 0.000 claims 3
- 208000020758 Peyronie disease Diseases 0.000 claims 3
- 206010040954 Skin wrinkling Diseases 0.000 claims 3
- 239000008176 lyophilized powder Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000193159 Hathewaya histolytica Species 0.000 claims 2
- 239000012614 Q-Sepharose Substances 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive effect Effects 0.000 claims 2
- 238000001042 affinity chromatography Methods 0.000 claims 2
- 238000005349 anion exchange Methods 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 238000004440 column chromatography Methods 0.000 claims 2
- 239000012141 concentrate Substances 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 claims 2
- 230000000409 histolytic effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000000047 product Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 235000013311 vegetables Nutrition 0.000 claims 2
- 102000013382 Gelatinases Human genes 0.000 claims 1
- 108010026132 Gelatinases Proteins 0.000 claims 1
- 108010013295 Microbial collagenase Proteins 0.000 claims 1
- 238000005571 anion exchange chromatography Methods 0.000 claims 1
- 108090001092 clostripain Proteins 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76347006P | 2006-01-30 | 2006-01-30 | |
| US60/763,470 | 2006-01-30 | ||
| US78413506P | 2006-03-20 | 2006-03-20 | |
| US60/784,135 | 2006-03-20 | ||
| US11/699,302 | 2007-01-29 | ||
| US11/699,302 US7811560B2 (en) | 2006-01-30 | 2007-01-29 | Compositions and methods for treating collagen-mediated diseases |
| PCT/US2007/002654 WO2007089851A2 (en) | 2006-01-30 | 2007-01-30 | Compositions and methods for treating collagen-mediated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011285435A Division JP2012070758A (ja) | 2006-01-30 | 2011-12-27 | コラーゲン媒介疾患を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009525283A JP2009525283A (ja) | 2009-07-09 |
| JP2009525283A5 true JP2009525283A5 (enExample) | 2012-02-23 |
| JP5309289B2 JP5309289B2 (ja) | 2013-10-09 |
Family
ID=38328033
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552504A Active JP5309289B2 (ja) | 2006-01-30 | 2007-01-30 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2011285435A Withdrawn JP2012070758A (ja) | 2006-01-30 | 2011-12-27 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2015072261A Active JP6230200B2 (ja) | 2006-01-30 | 2015-03-31 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2016196519A Active JP6389493B2 (ja) | 2006-01-30 | 2016-10-04 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2017173236A Active JP6851943B2 (ja) | 2006-01-30 | 2017-09-08 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2018126943A Active JP6792596B2 (ja) | 2006-01-30 | 2018-07-03 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2019229674A Active JP6944989B2 (ja) | 2006-01-30 | 2019-12-19 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2021070232A Active JP7191152B2 (ja) | 2006-01-30 | 2021-04-19 | コラーゲン媒介疾患を処置するための組成物および方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011285435A Withdrawn JP2012070758A (ja) | 2006-01-30 | 2011-12-27 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2015072261A Active JP6230200B2 (ja) | 2006-01-30 | 2015-03-31 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2016196519A Active JP6389493B2 (ja) | 2006-01-30 | 2016-10-04 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2017173236A Active JP6851943B2 (ja) | 2006-01-30 | 2017-09-08 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2018126943A Active JP6792596B2 (ja) | 2006-01-30 | 2018-07-03 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2019229674A Active JP6944989B2 (ja) | 2006-01-30 | 2019-12-19 | コラーゲン媒介疾患を処置するための組成物および方法 |
| JP2021070232A Active JP7191152B2 (ja) | 2006-01-30 | 2021-04-19 | コラーゲン媒介疾患を処置するための組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (16) | US7811560B2 (enExample) |
| EP (6) | EP2474321B1 (enExample) |
| JP (8) | JP5309289B2 (enExample) |
| KR (2) | KR20110046537A (enExample) |
| CN (2) | CN101400788B (enExample) |
| AU (2) | AU2007211313C1 (enExample) |
| BR (1) | BRPI0708017A2 (enExample) |
| CA (1) | CA2637262C (enExample) |
| DK (2) | DK2474321T3 (enExample) |
| ES (3) | ES2729941T3 (enExample) |
| HU (2) | HUE044220T2 (enExample) |
| IL (6) | IL291175B2 (enExample) |
| MX (1) | MX2008009756A (enExample) |
| NZ (2) | NZ569882A (enExample) |
| PT (2) | PT1987141T (enExample) |
| TR (1) | TR201903008T4 (enExample) |
| WO (1) | WO2007089851A2 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| US7811560B2 (en) * | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| US10071143B1 (en) | 2007-05-03 | 2018-09-11 | The Research Foundation For The State University Of New York | Methods for non-surgical treatment of carpal tunnel syndrome |
| EP2725035A1 (en) | 2007-10-02 | 2014-04-30 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
| US20100159564A1 (en) * | 2007-11-30 | 2010-06-24 | Dwulet Francis E | Protease resistant recombinant bacterial collagenases |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| EP2130551B1 (en) | 2008-06-02 | 2012-06-06 | Roche Diagnostics GmbH | Improved purification of collagenases from clostridium histolyticum liquid culture |
| US8236356B2 (en) | 2008-06-11 | 2012-08-07 | Roche Diagnostics Operations, Inc. | Growth medium for Clostridium histolyticum |
| WO2010102262A1 (en) | 2009-03-06 | 2010-09-10 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
| ES2385239B1 (es) | 2010-09-30 | 2013-06-19 | Proteos Biotech S.L.U. | Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno. |
| WO2012125948A1 (en) | 2011-03-16 | 2012-09-20 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
| MX350145B (es) | 2011-07-20 | 2017-08-28 | Mediwound Ltd | Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo. |
| WO2013059619A1 (en) * | 2011-10-21 | 2013-04-25 | Auxilium Pharmaceuticals, Inc. | Method of treating or reducing efp |
| EP4015627B1 (en) | 2012-01-12 | 2023-09-27 | Endo Global Ventures | Clostridium histolyticum enzyme |
| ITPD20120118A1 (it) | 2012-04-18 | 2013-10-19 | Fidia Farmaceutici | "nuovo processo di produzione e purificazione dell'enzima collagenasi da vibrio alginolyticus" |
| JP2015521169A (ja) | 2012-05-01 | 2015-07-27 | プロテオリース リミテッド | 抜歯する方法 |
| BR102012013110A2 (pt) | 2012-05-31 | 2014-05-27 | Cristalia Prod Quimicos Farm | Meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica |
| US9636385B2 (en) | 2012-10-24 | 2017-05-02 | The Research Foundation For The State University Of New York | Use of collagenase to treat glaucoma |
| US20150196625A9 (en) | 2013-01-07 | 2015-07-16 | Rudolph D. Paladini | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof |
| EP3834840B8 (en) | 2013-03-15 | 2025-09-17 | Endo Biologics Limited | Treatment method and product for uterine fibroids using purified collagenase |
| US20160000890A1 (en) * | 2013-03-15 | 2016-01-07 | Biospecifics Technologies Corp. | Thermosensitive hydrogel collagenase formulations |
| CA2915814A1 (en) * | 2013-06-18 | 2014-12-24 | Imprimis Pharmaceuticals Inc. | Local use of pentoxifylline to treat peyronie's disease |
| US10383875B2 (en) | 2013-06-18 | 2019-08-20 | Harrow Ip, Llc | Pharmaceutical formulations of xanthine or xanthine derivatives, and their use |
| US10117892B2 (en) * | 2013-08-29 | 2018-11-06 | Allergan, Inc. | Devices and methods for reducing the appearance of cellulite |
| CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
| CN105477627B (zh) * | 2014-09-19 | 2021-04-30 | 山东蓝金生物工程有限公司 | 治疗前列腺癌的组合物及其用途 |
| CN105412917B (zh) * | 2014-09-19 | 2021-04-30 | 达森生物药业有限公司 | 治疗实体瘤的抗癌组合物及其用途 |
| CN105412916B (zh) * | 2014-09-19 | 2021-04-30 | 达森生物药业有限公司 | 治疗乳腺癌的组合物及其用途 |
| CN105477628B (zh) * | 2014-09-19 | 2021-04-30 | 山东蓝金生物工程有限公司 | 抗癌组合物及其用途 |
| DE202014105440U1 (de) * | 2014-11-12 | 2016-02-15 | Bilz Werkzeugfabrik Gmbh & Co. Kg | Werkzeugaufnahme |
| KR101723168B1 (ko) | 2015-04-28 | 2017-04-05 | 주식회사 대웅 | 보툴리눔 독소의 제조를 위한 배지 조성물 |
| US10303245B2 (en) * | 2015-05-04 | 2019-05-28 | Adobe Inc. | Methods and devices for detecting and responding to changes in eye conditions during presentation of video on electronic devices |
| KR20230003601A (ko) | 2017-03-01 | 2023-01-06 | 엔도 벤쳐즈 리미티드 | 셀룰라이트를 평가하고 치료하기 위한 장치 및 방법 |
| KR20240001279A (ko) | 2017-03-28 | 2024-01-03 | 엔도 벤쳐즈 리미티드 | 개선된 콜라게나제 생성 방법 |
| WO2020021332A2 (en) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| WO2020021330A2 (en) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| JP7628492B2 (ja) | 2018-09-18 | 2025-02-10 | エンド グローバル エステティックス リミテッド | セルライトを治療するための組成物および方法 |
| MX2021008017A (es) | 2019-01-06 | 2021-08-05 | Endo Global Aesthetics Ltd | Formulaciones de colagenasa y metodos de produccion de las mismas. |
| CA3157517A1 (en) | 2019-10-15 | 2021-04-22 | The Johns Hopkins University | Treatment of uterine fibroids using purified collagenase |
| WO2023131588A1 (en) | 2022-01-05 | 2023-07-13 | Nordmark Pharma Gmbh | Culture medium for cultivating hathewaya histolytica (or clostridium histolyticum) and the production of one or more proteases |
| CN116102638B (zh) * | 2023-01-09 | 2025-05-16 | 中国农业科学院农产品加工研究所 | 基于亲和吸附富集骨胶原蛋白成骨活性肽的方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61289885A (ja) * | 1985-06-14 | 1986-12-19 | Nitta Zerachin Kk | コラゲナ−ゼおよびコラゲナ−ゼの製造方法 |
| JP2898022B2 (ja) * | 1989-09-05 | 1999-05-31 | 株式会社ニッピ | コラーゲン分解酵素の製造方法 |
| CA2047306A1 (en) * | 1990-07-23 | 1992-01-24 | Milan Holjevac | Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase |
| US5393792A (en) * | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
| US5462739A (en) * | 1991-11-21 | 1995-10-31 | Yeda Research And Development Co., Ltd. | Microdelivery device and method for enhanced drug administration to the eye |
| CA2138948A1 (en) * | 1992-06-22 | 1994-01-06 | Hun-Chi Lin | Molecular cloning of the genes responsible for collagenase production from clostridium histolyticum |
| JP3186881B2 (ja) * | 1993-02-18 | 2001-07-11 | 倉敷紡績株式会社 | 肝細胞の分離方法 |
| US5332503A (en) * | 1993-04-16 | 1994-07-26 | Baxter International Inc. | Process for purifying collagenase |
| CA2189646C (en) * | 1994-06-24 | 1999-05-25 | Francis E. Dwulet | A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum |
| US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
| CZ280397A3 (cs) * | 1995-03-16 | 1998-04-15 | Knoll Aktiengesellschaft | Nové, definované směsi enzymů pro získávání buněk a pro léčbu poranění |
| US5989888A (en) * | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
| ATE272109T1 (de) * | 1996-11-19 | 2004-08-15 | Roche Diagnostics Gmbh | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden |
| US5830741A (en) * | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
| US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
| JPH10262658A (ja) * | 1997-03-28 | 1998-10-06 | Kikkoman Corp | ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造 |
| US6022539A (en) | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
| CN1308442C (zh) * | 2001-07-02 | 2007-04-04 | 诺尔玛克药物有限责任及股份两合公司 | 纯化酶的方法和按此产生出的经纯化的酶以及该酶的用途 |
| EP1462519A1 (en) * | 2003-03-24 | 2004-09-29 | Boehringer Ingelheim Austria GmbH | Method and devices for producing biomolecules |
| JP4205496B2 (ja) * | 2003-06-19 | 2009-01-07 | 三菱化学株式会社 | 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法 |
| NZ548871A (en) * | 2004-01-30 | 2009-06-26 | Shire Pharmaceuticals Ireland | Use of arylsulfatase A for treating metachromatic leukodystrophy |
| US7355027B2 (en) * | 2004-06-16 | 2008-04-08 | Dynport Vaccine Company Llc | Bacillus anthracis protective antigen |
| EP1781697B1 (en) * | 2004-07-07 | 2009-04-22 | H.Lundbeck A/S | Novel carbamylated epo and method for its production |
| JP2008505928A (ja) * | 2004-07-08 | 2008-02-28 | アムジェン インコーポレーテッド | 治療用ペプチド |
| ES2548516T3 (es) * | 2005-01-21 | 2015-10-19 | The Research Foundation Of The State University Of New York | Métodos para el tratamiento de la capsulitis adhesiva |
| US7811560B2 (en) * | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
-
2007
- 2007-01-29 US US11/699,302 patent/US7811560B2/en active Active
- 2007-01-30 TR TR2019/03008T patent/TR201903008T4/tr unknown
- 2007-01-30 JP JP2008552504A patent/JP5309289B2/ja active Active
- 2007-01-30 ES ES12155233T patent/ES2729941T3/es active Active
- 2007-01-30 EP EP12155233.5A patent/EP2474321B1/en active Active
- 2007-01-30 ES ES07762860T patent/ES2709202T3/es active Active
- 2007-01-30 EP EP12155228A patent/EP2474319A1/en not_active Withdrawn
- 2007-01-30 BR BRPI0708017-4A patent/BRPI0708017A2/pt not_active Application Discontinuation
- 2007-01-30 KR KR1020117006197A patent/KR20110046537A/ko not_active Ceased
- 2007-01-30 EP EP18209918.4A patent/EP3508571B1/en active Active
- 2007-01-30 IL IL291175A patent/IL291175B2/en unknown
- 2007-01-30 NZ NZ569882A patent/NZ569882A/en unknown
- 2007-01-30 HU HUE12155233 patent/HUE044220T2/hu unknown
- 2007-01-30 KR KR1020087021302A patent/KR20080093142A/ko not_active Ceased
- 2007-01-30 NZ NZ593907A patent/NZ593907A/xx unknown
- 2007-01-30 EP EP07762860.0A patent/EP1987141B8/en active Active
- 2007-01-30 DK DK12155233.5T patent/DK2474321T3/da active
- 2007-01-30 ES ES18209918T patent/ES2992881T3/es active Active
- 2007-01-30 PT PT07762860T patent/PT1987141T/pt unknown
- 2007-01-30 PT PT12155233T patent/PT2474321T/pt unknown
- 2007-01-30 EP EP12155230A patent/EP2474320A1/en not_active Withdrawn
- 2007-01-30 AU AU2007211313A patent/AU2007211313C1/en active Active
- 2007-01-30 CN CN200780008746.5A patent/CN101400788B/zh active Active
- 2007-01-30 HU HUE07762860A patent/HUE041764T2/hu unknown
- 2007-01-30 MX MX2008009756A patent/MX2008009756A/es active IP Right Grant
- 2007-01-30 DK DK07762860.0T patent/DK1987141T3/en active
- 2007-01-30 CN CN201610369324.1A patent/CN105999244B/zh active Active
- 2007-01-30 WO PCT/US2007/002654 patent/WO2007089851A2/en not_active Ceased
- 2007-01-30 EP EP24194815.7A patent/EP4483952A3/en active Pending
- 2007-01-30 CA CA2637262A patent/CA2637262C/en active Active
-
2008
- 2008-07-17 IL IL192878A patent/IL192878A/en active IP Right Grant
-
2010
- 2010-04-13 US US12/759,065 patent/US20100233151A1/en not_active Abandoned
- 2010-07-16 US US12/837,933 patent/US20100330065A1/en not_active Abandoned
- 2010-08-30 US US12/871,159 patent/US20110158972A1/en not_active Abandoned
-
2011
- 2011-04-12 US US13/084,735 patent/US20110243920A1/en not_active Abandoned
- 2011-04-12 US US13/084,716 patent/US20110189153A1/en not_active Abandoned
- 2011-04-12 US US13/084,719 patent/US20110189163A1/en not_active Abandoned
- 2011-04-12 US US13/084,734 patent/US20110243909A1/en not_active Abandoned
- 2011-04-12 US US13/084,722 patent/US20110243908A1/en not_active Abandoned
- 2011-04-12 US US13/084,720 patent/US20110243919A1/en not_active Abandoned
- 2011-12-27 JP JP2011285435A patent/JP2012070758A/ja not_active Withdrawn
-
2012
- 2012-02-15 AU AU2012200863A patent/AU2012200863B2/en active Active
- 2012-12-13 US US13/713,019 patent/US20140004094A1/en not_active Abandoned
-
2015
- 2015-02-04 US US14/613,882 patent/US20160000889A1/en not_active Abandoned
- 2015-03-31 JP JP2015072261A patent/JP6230200B2/ja active Active
-
2016
- 2016-05-02 IL IL245434A patent/IL245434A/en active IP Right Grant
- 2016-05-20 US US15/160,392 patent/US20170087229A1/en not_active Abandoned
- 2016-10-04 JP JP2016196519A patent/JP6389493B2/ja active Active
-
2017
- 2017-08-28 IL IL254184A patent/IL254184B/en active IP Right Grant
- 2017-09-08 JP JP2017173236A patent/JP6851943B2/ja active Active
-
2018
- 2018-07-03 JP JP2018126943A patent/JP6792596B2/ja active Active
-
2019
- 2019-01-21 IL IL264361A patent/IL264361B/en active IP Right Grant
- 2019-12-19 JP JP2019229674A patent/JP6944989B2/ja active Active
-
2020
- 2020-09-13 IL IL277322A patent/IL277322B/en unknown
- 2020-10-02 US US17/062,372 patent/US20210106659A1/en not_active Abandoned
-
2021
- 2021-04-19 JP JP2021070232A patent/JP7191152B2/ja active Active
-
2022
- 2022-09-14 US US17/932,230 patent/US20230158127A1/en not_active Abandoned
-
2024
- 2024-05-13 US US18/662,818 patent/US20240299508A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009525283A5 (enExample) | ||
| JP6091596B2 (ja) | 高純度シクロペプチド化合物およびその製造方法と使用 | |
| JPS60215700A (ja) | 新規シクロスポリン類 | |
| TW414801B (en) | Crystalline forms of pyrrolidine derivatives and crystalline solvated forms thereof | |
| ES2562637T9 (es) | Método para la purificación industrial de ficotoxinas biológicamente activas | |
| JP2018507175A (ja) | 牛樟芝化合物、その製造方法及び用途 | |
| JP4257026B2 (ja) | トリプレニルフェノール化合物の選択的製造方法及びこれらの化合物の薬剤としての利用 | |
| JPWO2019045113A1 (ja) | イノシトール誘導体の混合物 | |
| JPH07330596A (ja) | 抗腫瘍剤 | |
| JPWO2004024185A1 (ja) | 医薬または化粧料 | |
| CN104231047B (zh) | 水溶性靶向激活的紫杉醇衍生物及其制备和用途 | |
| JP2008201688A (ja) | 皮膚老化防止剤、化粧料及び皮膚外用剤 | |
| CN106188242A (zh) | 一种新型环肽化合物在制备抑制结核杆菌的药物中的应用 | |
| CN101240014B (zh) | 一种具有生理活性的脂肽复合物及其制备方法与应用 | |
| JPH07188098A (ja) | ヒドロキシル化、あるいは酸化された脂質側鎖を有するモエノマイシン分解物およびモエノマイシン同族体、これらの化合物の製造方法および使用 | |
| JPH11127882A (ja) | 新規生理活性物質ｎｋ３０４２４ａ，ｎｋ３０４２４ｂ，それらの製造法およびそれらの用途 | |
| JPH0853387A (ja) | 新規化合物ｆ−１１２６３ | |
| JPS60120874A (ja) | Ｃｌ−１９５７ｂ抗菌性化合物およびその製法 | |
| JPS6084220A (ja) | 植物病原菌リゾ−プス・キネンシスの代謝産物リゾキシンを有効成分とする抗腫瘍剤 | |
| KR100882817B1 (ko) | 보툴리늄 독소를 유효성분으로 포함하는 지방세포 생착증진용 약학적 조성물 | |
| CN107602524A (zh) | 甲酰间苯三酚杂萜类化合物和其药物组合物与其制备方法及应用 | |
| JP3524164B2 (ja) | 抗腫瘍性物質アレナスタチンａおよび該化合物を活性成分として含有する抗腫瘍剤 | |
| RU2098422C1 (ru) | Производное пиранона, способ его получения и фармацевтическая композиция | |
| JPH09221428A (ja) | Ｗｂ２６６３ｂ物質を含有する免疫抑制剤 | |
| CN117298177A (zh) | 一种天然免疫调节剂及其制备方法 |